Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,487 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07717827 | Connectome-guided Onco-functional Resection With Tractography-Extended Neuronavigation in Brain Tumor Surgery(CORTEx) | recruiting | — | 400 | ARNAS Civico Di Cristina Benfratelli HospitalOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT06476808 | A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors. | recruiting | Phase 1 | 240 | Bristol-Myers SquibbINDUSTRY |
| 5 |
| Jul 20, 2026 |
| clinicaltrials |
| NCT07155226 | Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression(MOMENTUM) | recruiting | Phase 1 / Phase 2 | 84 | AstraZenecaINDUSTRY | 9 | Jul 20, 2026 | clinicaltrials |
| NCT05429632 | Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT(MO-TRANS) | recruiting | Phase 3 | 366 | Priothera SASINDUSTRY | 14 | Jul 17, 2026 | clinicaltrials |
| NCT05592938 | Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)(PRESERVE) | recruiting | N/A | 171 | University Health Network, TorontoOTHER | 10 | Jul 17, 2026 | clinicaltrials |
| NCT06788990 | FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC(FORTIFI-HN01) | recruiting | Phase 2 / Phase 3 | 650 | Bicara TherapeuticsINDUSTRY | 26 | Jul 17, 2026 | clinicaltrials |
| NCT07712120 | Brief Clinical Psychological Intervention With Biofeedback in Head and Neck Cancer(INTEGRATE-HNC) | recruiting | N/A | 58 | University of Turin, ItalyOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT06840977 | COLON ERDERLY LOW DOSE(CELOW) | recruiting | — | 51 | Matteo ClavarezzaOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06906341 | Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers | recruiting | Phase 2 | 270 | Corcept TherapeuticsINDUSTRY | 8 | Jul 16, 2026 | clinicaltrials |
| NCT06948448 | A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer | recruiting | Phase 2 | 144 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 6 | Jul 16, 2026 | clinicaltrials |
| NCT07707245 | Identification of Diagnostic and Prognostic Biomarkers in the Pathological Continuum of Bronco Chronic Obstructive Pulmonary Disease, Idiopathic Pulmonary Fibrosis and Pulmonary Neoplasia(RESPIRO) | recruiting | N/A | 120 | Fondazione Don Carlo Gnocchi ETSOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07704489 | San Raffaele Registry on Liver Cancer | recruiting | — | 4,000 | IRCCS San RaffaeleOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT05533697 | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 361 | ModernaTX, Inc.INDUSTRY | 7 | Jul 14, 2026 | clinicaltrials |
| NCT07700992 | A Liquid Biopsy for Pancreatic Cancer Early-detection and Disease Monitoring(PANXEON) | recruiting | — | 600 | Università Vita-Salute San RaffaeleOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07703761 | AI-driven Processing and Analysis of Glioma Imaging Data(GLIOMAID) | recruiting | — | 700 | Università degli Studi di TrentoOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT02813135 | European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors(ESMART) | recruiting | Phase 1 / Phase 2 | 472 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 6 | Jul 10, 2026 | clinicaltrials |
| NCT04815694 | THeragnostic Utilities for Neoplastic DisEases of the Rectum by MRI Guided Radiotherapy(THUNDER2) | recruiting | N/A | 179 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT05327894 | Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia(Interfant-21) | recruiting | Phase 3 | 160 | Princess Maxima Center for Pediatric OncologyOTHER | 24 | Jul 10, 2026 | clinicaltrials |
| NCT05911633 | BioPearl™ Microspheres Loaded With Doxorubicin for the Treatment of Unresectable Hepatocellular Carcinoma (HCC)(BIOPEARL-ONE) | recruiting | N/A | 50 | Terumo Europe N.V.INDUSTRY | 4 | Jul 10, 2026 | clinicaltrials |
| NCT06506084 | Observational Study on the Use of Ropeginterferon Alfa-2b in Polycythemia Vera (ROPEG-PV) | recruiting | — | 429 | FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETSOTHER | 2 | Jul 9, 2026 | clinicaltrials |
| NCT07203768 | A ELN-Multicenter Study on Phenotypic Evolution and Clinical Outcomes(ET2PV) | recruiting | — | 678 | FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETSOTHER | 5 | Jul 9, 2026 | clinicaltrials |
| NCT06140524 | A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma(LINKER-MGUS1) | recruiting | Phase 2 | 116 | Regeneron PharmaceuticalsINDUSTRY | 7 | Jul 8, 2026 | clinicaltrials |
| NCT07690540 | DETERMINANTS OF IMMUNOTHERAPY EFFICACY IN ENDOMETRIAL CANCER(iDEA) | recruiting | N/A | 510 | European Institute of OncologyOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT05581121 | PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer(PAROLA) | recruiting | Phase 3 | 510 | Institut Claudius RegaudOTHER | 4 | Jul 7, 2026 | clinicaltrials |
| NCT05768139 | First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors(PIKALO-1) | recruiting | Phase 1 / Phase 2 | 880 | Eli Lilly and CompanyINDUSTRY | 9 | Jul 7, 2026 | clinicaltrials |
| NCT06217822 | First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)(PAnTHA) | recruiting | Phase 1 | 198 | BayerINDUSTRY | 10 | Jul 7, 2026 | clinicaltrials |
| NCT06342401 | Early Onset Colorectal Cancer Detection(ENCODE) | recruiting | — | 400 | City of Hope Medical CenterOTHER | 4 | Jul 7, 2026 | clinicaltrials |
| NCT06342440 | Early Detection of Advanced Adenomas and Colorectal Cancer(AACRC) | recruiting | — | 2,000 | City of Hope Medical CenterOTHER | 5 | Jul 7, 2026 | clinicaltrials |
| NCT06796907 | A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2) | recruiting | Phase 1 / Phase 2 | 305 | GlaxoSmithKlineINDUSTRY | 23 | Jul 7, 2026 | clinicaltrials |
| NCT07304271 | Intraperitoneal Paclitaxel and Systemic Therapy Versus Systemic Therapy Alone in Gastric Cancer Patients With Peritoneal Metastasis(IPa-Gastric) | recruiting | Phase 3 | 262 | Magnus NilssonOTHER | 3 | Jul 7, 2026 | clinicaltrials |
| NCT02332668 | A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051) | recruiting | Phase 1 / Phase 2 | 370 | Merck Sharp & Dohme LLCINDUSTRY | 10 | Jul 6, 2026 | clinicaltrials |
| NCT04184973 | Efficacy and Safety of the CG-100 Intraluminal Bypass Device | recruiting | N/A | 250 | Colospan Ltd.INDUSTRY | 5 | Jul 6, 2026 | clinicaltrials |
| NCT04877522 | Asciminib Roll-over Study | recruiting | Phase 4 | 347 | Novartis PharmaceuticalsINDUSTRY | 29 | Jul 6, 2026 | clinicaltrials |
| NCT05496998 | Transcatheter Mitral Valve Replacement in Patients With Severe Symptomatic Mitral Regurgitation - APOLLO-EU Trial(APOLLO-EU) | recruiting | N/A | 400 | Medtronic CardiovascularINDUSTRY | 8 | Jul 6, 2026 | clinicaltrials |
| NCT05831397 | Extracellular Vesicles in Breast Cancer Patientsin Undergone Neoadjuvant Chemotherapy | recruiting | — | 35 | Istituti Clinici Scientifici Maugeri SpAOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07535112 | A Study to Learn More About How Safe BAY 3771249 is and How Well it Works in People With Advanced or Metastatic Colorectal Cancer That Has a KRAS G12D Mutation | recruiting | Phase 1 | 130 | BayerINDUSTRY | 10 | Jul 6, 2026 | clinicaltrials |
| NCT07685405 | Identification of Circulating Biomarkers Associated With Extracellular Vesicles in Sarcomas(BIOVES) | recruiting | — | 16 | Istituto Ortopedico RizzoliOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT05131022 | A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies | recruiting | Phase 1 | 572 | Nurix Therapeutics, Inc.INDUSTRY | 8 | Jul 2, 2026 | clinicaltrials |
| NCT06819007 | Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)(DO-01) | recruiting | Phase 3 | 582 | Daiichi SankyoINDUSTRY | 25 | Jul 2, 2026 | clinicaltrials |
| NCT07169734 | A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors | recruiting | Phase 1 / Phase 2 | 180 | Alentis Therapeutics AGINDUSTRY | 8 | Jul 2, 2026 | clinicaltrials |
| NCT04064060 | A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials | recruiting | Phase 3 | 665 | CelgeneINDUSTRY | 22 | Jul 1, 2026 | clinicaltrials |
| NCT05443126 | A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies | recruiting | Phase 1 / Phase 2 | 265 | Ellipses PharmaINDUSTRY | 8 | Jul 1, 2026 | clinicaltrials |
| NCT07098338 | A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)(LIBRA) | recruiting | Phase 2 | 278 | AstraZenecaINDUSTRY | 12 | Jul 1, 2026 | clinicaltrials |
| NCT06162221 | Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC | recruiting | Phase 1 / Phase 2 | 616 | Revolution Medicines, Inc.INDUSTRY | 13 | Jun 30, 2026 | clinicaltrials |
| NCT06747585 | A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors | recruiting | Phase 1 / Phase 2 | 170 | Alentis Therapeutics AGINDUSTRY | 8 | Jun 29, 2026 | clinicaltrials |
| NCT07049276 | The Multicentre Selective Lymphadenectomy Trial - 3(MSLT-3) | recruiting | N/A | 1,500 | Melanoma Institute AustraliaOTHER | 6 | Jun 29, 2026 | clinicaltrials |
| NCT04614103 | Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer | recruiting | Phase 2 | 170 | Iovance Biotherapeutics, Inc.INDUSTRY | 12 | Jun 26, 2026 | clinicaltrials |
| NCT06716814 | Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa(LIBERTY) | recruiting | Phase 3 | 104 | Swedish Orphan BiovitrumINDUSTRY | 7 | Jun 26, 2026 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials